H.C. Wainwright Remains a Buy on Verrica Pharmaceuticals (VRCA)

H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Verrica Pharmaceuticals (VRCAResearch Report) today and set a price target of $11.00. The company’s shares closed last Friday at $2.36.

According to TipRanks, Livnat is an analyst with an average return of -2.8% and a 39.90% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Jazz Pharmaceuticals, Pacira Pharmaceuticals, and ANI Pharmaceuticals.

Verrica Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $7.50.

See the top stocks recommended by analysts >>

VRCA market cap is currently $96.98M and has a P/E ratio of -2.31.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product VP-102, is a proprietary topical therapy used in common skin indications including Molluscum contagiosum and Verruca Vulgaris. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Read More on VRCA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More